logo
Plus   Neg
Share
Email

Amgen: CANDOR Study Supports Combination Of KYPROLIS, DARZALEX - Quick Facts

Amgen (AMGN) announced additional results from the primary analysis of the phase 3 CANDOR study evaluating KYPROLIS (carfilzomib) in combination with dexamethasone and DARZALEX (daratumumab) compared to KYPROLIS and dexamethasone alone in patients with relapsed or refractory multiple myeloma. The primary analysis of the CANDOR study supports the combination of KYPROLIS and DARZALEX, two targeted agents for multiple myeloma.

In the study, the treatment With KYPROLIS, Dexamethasone and DARZALEX resulted in a significant progression-free survival benefit. A reduction of 37% was recorded in the risk of progression or death compared to KYPROLIS and Dexamethasone.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients. Ferring Pharmaceuticals US is recalling various nasal sprays citing superpotency or amounts of desmopressin higher than specified, the U.S. Food and Drug Administration announced in a statement. The recall involves all lots on the market of DDAVP Nasal Spray 10 mcg/0.1mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1mL, and STIMATE Nasal Spray 1.5 mg/mL. U.S. President Donald Trump has issued executive orders to ban Chinese mobile application TikTok as well as WeChat, citing a threat to national security and its economy. China's ByteDance Ltd. owns TikTok, a video-sharing mobile app, while Tencent Holdings Ltd. owns WeChat, a messaging, social media, and electronic payment app.
Follow RTT